The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

39 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
11
Dipeptidyl Nitroalkenes as Potent Reversible Inhibitors of Cysteine Proteases Rhodesain and Cruzain.EBI
Universitat Jaume I
1
Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents.EBI
University of Messina
13
Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation.EBI
University of Messina
11
Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors.EBI
University of Messina
9
Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors.EBI
University of Messina
5
Dipeptidyl-alpha,beta-epoxyesters as potent irreversible inhibitors of the cysteine proteases cruzain and rhodesain.EBI
Universitat Jaume I
26
Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database.EBI
University of Mississippi
24
Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.EBI
University of Mississippi
8
Allicin and derivates are cysteine protease inhibitors with antiparasitic activity.EBI
University of WüRzburg
4
Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain.EBI
University of Messina
10
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.EBI
University of Duisburg-Essen
9
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.EBI
University of W£Rzburg
10
Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases.EBI
University of California
31
Structure-guided development of selective TbcatB inhibitors.EBI
University of California
3
Synthesis of macrocyclic trypanosomal cysteine protease inhibitors.EBI
Scripps Florida
8
Identification of constrained peptidomimetics carrying a Michael acceptor warhead as antitrypanosomal agents.EBI
University of Messina
46
Synthesis and structure-activity relationship studies of cruzain and rhodesain inhibitors.EBI
Universidade Federal Do Rio Grande Do Sul
10
Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei rhodesiense.EBI
University of Messina
36
Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.EBI
University of Wuerzburg
11
Development of Urea-Bond-Containing Michael Acceptors as Antitrypanosomal Agents Targeting Rhodesain.EBI
University of Messina
31
New peptidomimetic rhodesain inhibitors with improved selectivity towards human cathepsins.EBI
Johannes Gutenberg University
11
Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain.EBI
University of California San Francisco
15
Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi.EBI
University of California San Francisco
15
Structure-Based Optimization of Quinazolines as Cruzain and EBI
Federal University of Minas Gerais (Ufmg)
30
Fluorovinylsulfones and -Sulfonates as Potent Covalent Reversible Inhibitors of the Trypanosomal Cysteine Protease Rhodesain: Structure-Activity Relationship, Inhibition Mechanism, Metabolism, and In Vivo Studies.EBI
Johannes Gutenberg University
7
Computer-aided design of 1,4-naphthoquinone-based inhibitors targeting cruzain and rhodesain cysteine proteases.EBI
Federal University of Alagoas
4
Synthesis and biological screening of thiosemicarbazones of substituted 3-acetylcoumarins having d-glucose moiety.EBI
Institute For Advanced Technology (Vietnam Academy of Military Science and Technology)
5
Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.EBI
Universidade Federal De Minas Gerais
2
Drug Synergism: Studies of Combination of RK-52 and Curcumin against Rhodesain of EBI
University of Messina
3
Nostotrebin 6 Related Cyclopentenediones and δ-Lactones with Broad Activity Spectrum Isolated from the Cultivation Medium of the Cyanobacterium EBI
University of Halle-Wittenberg
15
Optimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African Trypanosomiasis.EBI
University of Messina
6
Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?EBI
University of S£O Paulo
14
New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8.EBI
Johannes Gutenberg-Universit£T Mainz
16
Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates.EBI
Universitat Jaume I
1
Discovery of a quinoline-based phenyl sulfone derivative as an antitrypanosomal agent.EBI
Jackson State University
8
Bistacrines as potential antitrypanosomal agents.EBI
Julius-Maximilians-University of W£Rzburg
34
2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.EBI
Eth Zurich
26
Repurposing a Library of Human Cathepsin L Ligands: Identification of Macrocyclic Lactams as Potent Rhodesain and Trypanosoma brucei Inhibitors.EBI
Eth Zurich
17
Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).EBI
University of Messina